Gemphire Therapeutics’ (GEMP) “Buy” Rating Reiterated at Roth Capital

Roth Capital reiterated their buy rating on shares of Gemphire Therapeutics (NASDAQ:GEMP) in a report released on Friday morning. They currently have a $30.00 price objective on the stock.

Other research analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Gemphire Therapeutics from a hold rating to a buy rating and set a $10.00 price objective on the stock in a research report on Thursday, November 16th. Canaccord Genuity reiterated a buy rating and set a $31.00 price objective on shares of Gemphire Therapeutics in a research report on Monday, October 23rd. Piper Jaffray Companies reissued an overweight rating and set a $22.00 target price on shares of Gemphire Therapeutics in a research note on Friday, October 27th. Finally, HC Wainwright reissued a buy rating and set a $22.00 target price (up from $21.00) on shares of Gemphire Therapeutics in a research note on Tuesday, November 14th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $22.17.

Gemphire Therapeutics (NASDAQ:GEMP) traded up $0.26 during mid-day trading on Friday, reaching $8.13. 25,600 shares of the company’s stock were exchanged, compared to its average volume of 63,551. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.17 and a quick ratio of 4.17. Gemphire Therapeutics has a fifty-two week low of $7.20 and a fifty-two week high of $21.59. The company has a market capitalization of $86.45, a PE ratio of -2.41 and a beta of 2.92.

Gemphire Therapeutics (NASDAQ:GEMP) last posted its quarterly earnings data on Monday, November 13th. The company reported ($0.82) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.14). equities research analysts forecast that Gemphire Therapeutics will post -3.31 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the company. Advisory Services Network LLC purchased a new stake in shares of Gemphire Therapeutics during the second quarter valued at $139,000. Renaissance Technologies LLC purchased a new stake in Gemphire Therapeutics in the first quarter worth about $184,000. Vanguard Group Inc. lifted its stake in Gemphire Therapeutics by 137.6% in the second quarter. Vanguard Group Inc. now owns 30,898 shares of the company’s stock worth $399,000 after acquiring an additional 17,892 shares during the period. GM Advisory Group Inc. purchased a new stake in Gemphire Therapeutics in the second quarter worth about $457,000. Finally, Comerica Bank purchased a new stake in Gemphire Therapeutics in the third quarter worth about $850,000. 32.11% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Gemphire Therapeutics’ (GEMP) “Buy” Rating Reiterated at Roth Capital” was first reported by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://weekherald.com/2017/12/26/gemphire-therapeutics-gemp-buy-rating-reiterated-at-roth-capital-3.html.

About Gemphire Therapeutics

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

Analyst Recommendations for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply